Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Gains from Investment Securities (2019 - 2025)

Immunocore Holdings' Gains from Investment Securities history spans 3 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to $1.1 million; the TTM value through Dec 2025 reached $4.6 million, changed N/A, while the annual FY2025 figure was $4.6 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2025 was $1.1 million at Immunocore Holdings, down from $2.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.1 million in Q3 2025 and bottomed at -$953000.0 in Q2 2024.
  • The 3-year median for Gains from Investment Securities is $2000.0 (2024), against an average of $245090.9.
  • The largest YoY upside for Gains from Investment Securities was 455.31% in 2025 against a maximum downside of 25550.0% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at -$632000.0 in 2023, then increased by 7.59% to -$584000.0 in 2024, then surged by 281.16% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Gains from Investment Securities are $1.1 million (Q4 2025), $2.1 million (Q3 2025), and $2.0 million (Q2 2025).